<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02322268</url>
  </required_header>
  <id_info>
    <org_study_id>6370700</org_study_id>
    <nct_id>NCT02322268</nct_id>
  </id_info>
  <brief_title>RCT Evaluating Effects of Cosmos Caudatus (Ulam Raja) in T2DM Patients</brief_title>
  <official_title>Metabolomic Profiling on The Effect of Cosmos Caudatus (Ulam Raja) Supplementation in Patients With Type 2 Diabetes: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universiti Putra Malaysia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universiti Putra Malaysia</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether Cosmos caudatus is effective as an adjuvant
      therapy for type 2 Diabetes Mellitus.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Cosmos caudatus (C. caudatus) ethanol extract has been reported to have
      extraordinary high antioxidant capacity compared to other plants. Furthermore it has been
      shown to reduce the plasma blood glucose and lipid profile significantly in an animal model.
      However, no study has been reported on its effectiveness in human. Therefore, we plan to
      conduct a randomized controlled trial to evaluate the effectiveness and safety of C. caudatus
      on glycemic status, oxidative stress markers, inflammatory markers, lipid profile in patients
      with type 2 diabetes. Besides, metabolomics approach will be carried out to compare the
      metabolite changes between diabetic C. caudatus treated and control patients.

      Methods: A single-center randomized, controlled, two-arm parallel design clinical trial will
      be carried out in Malaysia. This study enrol 92 patients diagnosed with type 2 diabetes.
      Diabetic patients who meet eligibility criteria will be randomly allocated to two groups,
      which are C. caudatus treatment group and control group. Both groups will be compared on the
      primary and secondary outcomes at baseline, 4, 8, and 12 weeks. The serum and urine
      metabolome of both groups will be examined using proton NMR spectroscopy.

      Discussion: The study will provide insights into the potential beneficial effect of C.
      caudatus in type 2 diabetic patients. In addition, the therapeutic effect of C. caudatus
      towards type 2 diabetes will reflect as a change of metabolite profile in urine and serum.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2014</start_date>
  <completion_date type="Actual">November 2015</completion_date>
  <primary_completion_date type="Actual">November 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glycemic control</measure>
    <time_frame>1 month</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Liver profile</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal profile</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Metabolite profile</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory marker</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Lipid profile</measure>
    <time_frame>1 month</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">101</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Diabetic Cosmos caudatus treated group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Subjects in this arm will receive Cosmos caudatus for 8 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Diabetic control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Subject in this group will not receive Cosmos caudatus. However, they will be educated for the same calorie intake and lifestyle intervention as in Cosmos caudatus treated group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Cosmos Caudatus</intervention_name>
    <description>15g of Cosmos caudatus consumed with lunch or dinner</description>
    <arm_group_label>Diabetic Cosmos caudatus treated group</arm_group_label>
    <other_name>Ulam Raja</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Confirmed type 2 diabetes with at least 6 months diagnosis

          2. BMI between 18.5-40 kg/ m2

          3. Able to comply to the study protocol

          4. They are treated with stabilized dose of oral diabetic agents

        Exclusion Criteria:

          1. Pregnant and lactating

          2. Have any gastrointestinal disorder that interferes the bowel function, severe hepatic
             or renal disease (dialysis), an infection that requires antibiotics within three weeks

          3. They are currently on insulin regimen.

          4. Individuals on the following drugs which will possibly have herb-drug interaction:
             anticoagulant such as warfarin and aspirin, corticosteroids (Prednisolone),
             fluoroquinolones (ciprofloxacin, levofloxacin), doxorubicin, cisplatin, cyclosporine,
             and digoxin
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>30 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shi Hui Cheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universiti Putra Malaysia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Serdang</name>
      <address>
        <city>Serdang</city>
        <state>Selangor</state>
        <zip>43400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/diabetestype2.html</url>
    <description>Type 2 Diabetes</description>
  </link>
  <link>
    <url>http://www.nlm.nih.gov/medlineplus/</url>
    <description>Medlineplus</description>
  </link>
  <verification_date>November 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2014</study_first_submitted>
  <study_first_submitted_qc>December 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>November 30, 2015</last_update_submitted>
  <last_update_submitted_qc>November 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universiti Putra Malaysia</investigator_affiliation>
    <investigator_full_name>Cheng Shi Hui</investigator_full_name>
    <investigator_title>Cheng Shi Hui</investigator_title>
  </responsible_party>
  <keyword>Type 2 Diabetes Mellitus</keyword>
  <keyword>Cosmos Caudatus</keyword>
  <keyword>Ulam Raja</keyword>
  <keyword>Metabolomic profiling</keyword>
  <keyword>antioxidant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

